| Species |
Human |
| Protein Construction |
VEGF121 (Ala27-Arg147)_x000D_
Accession # P15692-9 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 90% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized VEGF121, Human at 0.5μg/ml (100μl/well) on the plate can bind Human VEGF R1, His Tag. Test result was comparable to standard batch.
Measured by a reporter gene assay using HEK293TKDRNFAT Cell line. The ED50 for this effect is< 8 ng/mL. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
14.07 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 15-25 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. |
| Synonyms |
VEGF; VEGFA; MVCD1; VAS; VEGFMGC70609; VPF; RP1-261G23.1; MGC70609 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
